



# Medications for Osteoporosis: An Update

B.C. Provincial Academic Detailing (PAD) Service

December 2023

## Cover page

1. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>
2. Theriault G et al. CTFPHC. Recommendations on screening for primary prevention of fragility fractures. CMAJ 2023;195:E639-49
3. Gates M et al. CTFPHC. Systematic Rev 2023;12:51
4. American College of Physicians. Osteoporosis clinical practice guideline. Ann Intern Med 2023;176:224-38
5. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
6. Handel M et al. BMJ 2023;381:e068033
7. Compston J. Endocrine 2018;61:7-16

## Indications & basis of approval

1. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>
2. Health Canada Drug and Health Product Register. <https://hpr-rps.hres.ca/>
3. U.S. Food & Drug Administration. FDA Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
4. U.S. Food & Drug Administration. Osteoporosis Drug Development Public Workshop. <https://www.federalregister.gov/documents/2015/09/10/2015-22784/osteoporosis-drug-development-public-workshop-request-for-comments>
5. U.S. Food & Drug Administration Table of Surrogate Endpoints. <https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure>
6. Kehoe T et al. Br J Clin Pharmacol 2019;85:1208-12
7. Reid I et al. Osteopenia zoledronic acid trial. N Engl J Med 2018;379:2407-16
8. Drug Coverage Decision for BC Pharmacare. Jan 17, 2023. [https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/denosumab\\_for\\_cancer\\_patients\\_osteoporosis\\_review\\_dds\\_2.pdf](https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/denosumab_for_cancer_patients_osteoporosis_review_dds_2.pdf)

## BC PharmaCare coverage & annual drug cost

1. BC PharmaCare Formulary Search. <https://pharmacareformularysearch.gov.bc.ca/>
2. McKesson Canada – PharmaClik. <https://pharmaclik-login.mckesson.ca/>
3. Canada's Drug and Health Technology Agency. <https://www.cadth.ca/denosumab-1>
4. Canada's Drug and Health Technology Agency. <https://www.cadth.ca/teriparatide-rdna-origin-injection-4>
5. Canada's Drug and Health Technology Agency. <https://www.cadth.ca/romosozumab>

## Osteoporosis medications: evidence overview

1. American College of Physicians. Osteoporosis clinical practice guideline. Ann Intern Med 2023;176:224-38
2. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
3. FREEDOM denosumab trial. N Engl J Med 2009;361:756-65
4. VERO teriparatide vs risedronate trial. Lancet 2018;391:230-40
5. VERO teriparatide vs risedronate trial. Osteo International 2020;31:1935-42
6. ARCH romosozumab vs alendronate trial. N Engl J Med 2017;377:1417-27
7. U.S. Food & Drug Administration. Romosozumab review. 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/761062Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000TOC.cfm)
8. Health Canada Drug and Health Product Register. Romosozumab summary basis of decision. 2019. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00451>
9. European Medicines Agency. Romosozumab review. 2020. <https://www.ema.europa.eu/en/medicines/human/EPAR/evenity>

## **Bisphosphonates, denosumab: patient population estimates**

1. FIT 1 trial alendronate. Lancet 1996;348:1535-41
2. FIT 2 trial alendronate. JAMA 1998;280:2077-82
3. FREEDOM denosumab trial. N Engl J Med 2009;361:756-65
4. FREEDOM denosumab trial. J Bone Min Res 2012;27:211-18
5. American College of Physicians. Osteoporosis clinical practice guideline. Ann Intern Med 2023;176:224-38
6. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
7. Allen C et al. Cochrane Database Syst Rev 2016;CD001347

## **Bisphosphonates: shared decision making**

1. FIT 1 trial alendronate. Lancet 1996;348:1535-41
2. CADTH Health Technology Review. Bisphosphonates 2021. <https://www.cadth.ca/bisphosphonate-drugs-treatment-osteoporosis-post-menopausal-women>
3. HORIZON RFT zoledronic acid. NEJM 2007;357:1799-809
4. FIT 2 trial alendronate. JAMA 1998;280:2077-82
5. Gates M et al. CTFPHC. Systematic Rev 2023;12:51

## **Older adults with frailty & multimorbidity**

1. Handel M et al. BMJ 2023;381:e068033
2. American College of Physicians. Osteoporosis clinical practice guideline. Ann Intern Med 2023;176:224-38
3. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
4. Osteoporosis Canada. 2015. Long term care guideline. CMAJ 2015;187:1135-44
5. Gates M et al. Systematic Rev 2023;12:51
6. Deardorff W et al. Time to benefit bisphosphonates. JAMA Intern Med 2022;182:33-41
7. FIT 1 trial alendronate. Lancet 1996;348:1535-41
8. HIP trial risedronate. N Engl J Med 2001;344:333-40
9. HORIZON PFT trial zoledronic acid. N Engl J Med 2007;356:1809-22
10. HORIZON RFT trial zoledronic acid. N Engl J Med 2007;357:1799-809
11. Reid I et al. Osteopenia zoledronic acid trial. N Engl J Med 2018;379:2407-16
12. FREEDOM denosumab trial. N Engl J Med 2009;361:756-65
13. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>

## **Exit strategies & transitions**

1. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>
2. U.S. Food & Drug Administration. FDA Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. Agency for Healthcare Research and Quality. Long-term drug therapy and drug holidays for osteoporosis. Systematic review. 2019. <https://effectivehealthcare.ahrq.gov/products/osteoporosis-fracture-prevention/research>
4. FLEX extension trial alendronate. JAMA 2006;296:2927-38
5. BLACK atypical femur fracture risk with bisphosphonates N Engl J Med 2020;383:743-53.
6. HORIZON PFT extension trial zoledronic acid. J Bone Min Research 2012;27:243-54
7. American Association Clinical Endocrinologists – American College of Endocrinology guidelines. Endocrine Pract 2020;26 (Suppl1):1-44
8. Cummings S et al. FREEDOM denosumab extension. J Bone Min Research 2018;33:188-89
9. U.S. Food & Drug Administration. Teriparatide osteosarcoma review. 2020. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2021/021318Orig1s053.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021318Orig1s053.pdf)
10. U.S. Food & Drug Administration. Romosozumab review. 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/761062Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000TOC.cfm)
11. Reid I, Billington E. Lancet 2022;399:1080-92

## **Bisphosphonates: Clinical considerations**

1. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>

2. U.S. Food & Drug Administration. FDA Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. Reid I, Billington E. Lancet 2022;399:1080-92
4. Ruggiero, SL et al. J Oral Maxillofac Surg, 2022;80:5:920-43
5. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
6. Black DM et al. New Engl J Med 2020;383:743-53
7. Park-Wylie LY et al. JAMA: 2011;305:8:783-789
8. Agency for Healthcare Research and Quality. Long-term drug therapy and drug holidays for osteoporosis. Systematic review. 2019. <https://effectivehealthcare.ahrq.gov/products/osteoporosis-fracture-prevention/research>
9. Chartrand NA et al. Journal of Ocular Pharmacology and Therapeutics 2023;39:3-16
10. Gaudin E et al. J Clin Periodontol 2015;42:922

### **Denosumab: Clinical considerations**

1. Health Canada Drug Product Database, Prolia [https://pdf.hres.ca/dpd\\_pm/00068834.PDF](https://pdf.hres.ca/dpd_pm/00068834.PDF)
2. U.S. Food & Drug Administration. FDA Approved Drugs, Prolia [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/125320s211bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125320s211bl.pdf)
3. Reid I, Billington E. Lancet 2022;399:1080-92
4. Cowan A et al. Journal of Bone and Mineral Research March 2023; Accessed online Mar 27, 2023 <https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4804>
5. Diker-Cowan T et al. J Clin Endocrinol Metab 2020;105:1641–1658
6. Everts-Graber J et al. Journal of Bone and Mineral Research Plus, 2022;6:10:1-9
7. Bone H et al. Lancet Diabetes and Endocrinology 2017;5:7:513-523
8. Ruggiero S et al. J Oral Maxillofac Surg 2022;80:920-942
9. Watts N et al. J Clin Endocrinol Metab, 2019;104:6:2443–2452
10. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
11. Kendler D et al. Adv Ther 2022;39:58-74.
12. Gopaul A et al. Archives of Osteoporosis. 2021;16:1:116
13. Drug Coverage Decision for BC Pharmacare. Jan 17, 2023 [https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/denosumab\\_for\\_ckd\\_patients\\_-osteoporosis\\_review\\_dds\\_3.pdf](https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/denosumab_for_ckd_patients_-osteoporosis_review_dds_3.pdf)
14. Thongprayoon C et al. Osteo Internat 2018;29:1737-45

### **Evidence for Practice**

1. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>
2. U.S. Food & Drug Administration. FDA Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. Handel M et al. BMJ 2023;381:e068033
4. Simpson E et al. Bone 2020;130:115081
5. American College of Physicians. Osteoporosis clinical practice guideline. Ann Intern Med 2023;176:224-38
6. American College of Physicians. Osteoporosis systematic review and network meta-analysis. Ann Intern Med 2023;176:182-95
7. Drug Coverage Decision for BC Pharmacare. Jan 17, 2023 [https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/denosumab\\_for\\_cancer\\_patients\\_-osteoporosis\\_review\\_dds\\_2.pdf](https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/denosumab_for_cancer_patients_-osteoporosis_review_dds_2.pdf)
8. Allen C et al. Cochrane Database Syst Rev 2016;CD001347
9. Deardorff W et al. Time to benefit bisphosphonates. JAMA Intern Med 2022;182:33-41
10. American Association Clinical Endocrinologists – American College of Endocrinology guidelines. Endocrine Pract 2020;26 (Suppl1):1-44
11. Reid I, Billington E. Lancet 2022;399:1080-92

### **Appendix: Vitamin D & Calcium Supplementation**

1. US Preventive Services Task Force. Vitamin d, calcium. JAMA 2018;319:1592-99
2. US Preventive Services Task Force. Falls prevention. JAMA 2018;319:1696-1704
3. US Preventive Services Task Force. Vitamin d screening. JAMA 2021;325:1436-42
4. Bolland M, Grey A, Avenell A. Lancet Diabetes Endocrinol 2018;6:847-58

5. National Academies. 2011. Dietary reference intakes calcium and vitamin d. <https://www.ncbi.nlm.nih.gov/books/NBK56070/>
6. Ross A et al. J Clin Endocrinol Metab 2011;96:53-58
7. Manson J et al. N Engl J Med 2016;375:1817-20
8. Bolland M, Avenell A, Grey A. BMJ 2016;355:i6201
9. Reid I, Bolland M. Nutrients 2020;12:1011
10. Cummings S, Rosen C. N Engl J Med 2022;387:368-70
11. Reid I, Billington E. Lancet 2022;399:1080-92
12. Gallagher J, Rosen C. Lancet Diabetes Endocrinol 2023;11:362-74
13. Health Canada Drug Product Database. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>
14. RECORD trial. Lancet 2005;365:1621-28